A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)
A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)
The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.
Inclusion criteria:
Exclusion criteria:
Other protocol defined inclusion/ exclusion criteria applied
Mobile, Alabama 36688, United States
San Francisco, California 94143-0128, United States
Tampa, Florida 33612, United States
Indianapolis, Indiana 46202, United States
Louisville, Kentucky 40202, United States
New Orleans, Louisiana 70115, United States
Detroit, Michigan 48201, United States
Littleton, New Hampshire 03561, United States
New York, New York 10032, United States
Columbus, Ohio 43210, United States
Bethlehem, Pennsylvania, United States
Pittsburgh, Pennsylvania 15213, United States
Houston, Texas 77030-4009, United States
Chuo-ku, Tokyo, Japan
Lin-Ko, 33305, Taiwan